Download PDF
Pharmacopsychiatry 1999; 32(4): 142-147
DOI: 10.1055/s-2007-979220
Original Papers

© Georg Thieme Verlag Stuttgart · New York

Amantadine Revisited: An Open Trial of Amantadinesulfate Treatment in Chronically Depressed Patients with Borna Disease Virus Infection

R. Ferszt1 , K.-P. Kühl1 , L. Bode4 , E. W. Severus2 , B. Winzer2 , A. Berghöfer2 , G. Beelitz1 , B. Brodhun4 , B. Müller-Oerlinghausen2 , H. Ludwig3
  • 1Department of Gerontopsychiatry, Freie Universität Berlin, Germany
  • 2Psychiatric Hospital and Policlinic, Freie Universität Berlin, Germany
  • 3Institute of Virology, Freie Universität, Berlin, Germany
  • 4Robert Koch-Institute, Berlin, Germany
Further Information

Publication History

Publication Date:
20 April 2007 (online)

Also available at
  PDF Download  Permissions and Reprints

Abstract

Amantadinesulfate is a well known substance which has proven useful in the treatment and prophylaxis of viral infections, in treating symptoms of Parkinson's disease, cocaine dependence, and apathy in multiple sclerosis. It has also been reported as having mild antidepressive effects not sufficient to warrant its use as an antidepressant. Striking antidepressive effects in some patients have been attributed to its antiviral activity against human Borna disease virus (BDV) infection which is frequently seen in patients with depressive episodes. In this 8 to 12 week open study of oral amantadine in 30 depressed patients with various states of BDV infection we found a significant antidepressive response in 19 of 30. Peripheral BDV antigen indicating acute infection was cleared in both responders and non-responders, but only in responders peripheral infection was significantly reduced.

      >